Most patients with rectal cancer receive neoadjuvant therapy. This usually causes a decrease in tumor size. In approximately 20% of patients who receive neoadjuvant therapy, the tumor disappears completely (complete pathological response), showing as a scar on the rectal mucosa, not noticeable from the rectal serosa, from outside the rectum, difficulting the identification of the tumor location by the surgeon.

Rectoscope (p201630551) allows the surgeon to view the illuminated rectum from the patient's abdomen, determining the appropriate point of section of the rectum.

Inclusion Criteria:

• Men and women over 18 years old.
• Patients with rectal cancer (15 cm or less from the anal margin), whether or not they have received neoadjuvant treatment, in whom cancer surgery is to be performed through the anterior (abdominal) route, whether laparoscopic or not.
• Patients who accept their participation in this study, after explaining the study details.
• Patients who sign the informed consent.

Exclusion Criteria:

• Patients who are going to undergo an abdominoperineal amputation or transanal surgery for rectal cancer.
• Patients who do not accept their participation in this study.